Waters Launches Charge Detection Mass Spectrometry Technology
Waters Corporation (NYSE: WAT) has unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterization for the broadest range of mega-mass biomolecules.
The technology enables accurate analysis of protein complexes, nucleic acids, and gene delivery vehicles, including distinguishing between empty, partial, full, and overfull viral vector capsids in less than 10 minutes per sample.
This innovation addresses the significant challenges scientists face in analyzing large and heterogeneous drug modalities, particularly with the rapid growth of cell and gene therapies, mRNA, and complex protein therapeutics.
Existing tools are limited in resolution, sensitivity, and compliance-readiness.
The Waters Xevo CDMS is designed to accelerate the development of next-generation biotherapeutics.
Author's summary: Waters launches CDMS technology for biotherapeutics development.
More News
- PAL Named 2nd Best Airline in SEA, Announces $315M Upgrade Plan
- Radiant chooses Tennessee for first reactor factory - Nuclear Engineering International
- New York Approves Transmission Line for Micron’s $100 Billion Semiconductor Megafab - EconoTimes
- Bolton, 76, indicted under US Espionage Act, faces 180 years in prison - Lynnwood Times
- These Are the Lifetime Fashion Buys Worth Your Attention
- NEA disburses nearly PHP 2B in loans to electric cooperatives in Q3
- Los Altos football moves step closer to league title with win over Chino
- Ex-Roma star has one major question about Joshua Zirkzee ahead of possible swoop for Man Utd forward
- GTA 6 LIVE: Next official announcement date revealed
- Pinto nets shootout winner to lead Senators past Kraken 4-3